Desde mi punto de vista noticia ESPECTACULAR. Desmonta la tesis de los cortos de la bancarrota y hay un 50% de SI apostando a que NVAX se iba a la bancarrota….https://finance.yahoo.com/news/novavax-resolves-gavi-dispute-over-covid-19-vaccines-113038472.html
Desde mi punto de vista noticia ESPECTACULAR. Desmonta la tesis de los cortos de la bancarrota y hay un 50% de SI apostando a que NVAX se iba a la bancarrota….https://finance.yahoo.com/news/novavax-resolves-gavi-dispute-over-covid-19-vaccines-113038472.html
Desde mi punto de vista noticia ESPECTACULAR. Desmonta la tesis de los cortos de la bancarrota y hay un 50% de SI apostando a que NVAX se iba a la bancarrota….https://finance.yahoo.com/news/novavax-resolves-gavi-dispute-over-covid-19-vaccines-113038472.html
Desde mi punto de vista noticia ESPECTACULAR. Desmonta la tesis de los cortos de la bancarrota y hay un 50% de SI apostando a que NVAX se iba a la bancarrota….https://finance.yahoo.com/news/novavax-resolves-gavi-dispute-over-covid-19-vaccines-113038472.html
28 de Febrero ERhttps://ir.novavax.com/uk/press-releases/2024-02-20-Novavax-to-Host-Conference-Call-to-Discuss-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Operational-Highlights-on-February-28%2C-2024
28 de Febrero ERhttps://ir.novavax.com/uk/press-releases/2024-02-20-Novavax-to-Host-Conference-Call-to-Discuss-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Operational-Highlights-on-February-28%2C-2024
El ensayo de fase 3 confirma la alta eficacia de la vacuna contra la malaria R21/Matrix-Mhttps://www.reuters.com/business/healthcare-pharmaceuticals/second-malaria-vaccine-highly-protective-trial-results-show-2024-02-01/https://www.precisionvaccinations.com/2024/02/01/malaria-vaccine-adjuvant-found-very-effectivehttps://www.miragenews.com/phase-3-trial-confirms-high-efficacy-of-1166322/Esta buenísima noticia traerá un -15%
El ensayo de fase 3 confirma la alta eficacia de la vacuna contra la malaria R21/Matrix-Mhttps://www.reuters.com/business/healthcare-pharmaceuticals/second-malaria-vaccine-highly-protective-trial-results-show-2024-02-01/https://www.precisionvaccinations.com/2024/02/01/malaria-vaccine-adjuvant-found-very-effectivehttps://www.miragenews.com/phase-3-trial-confirms-high-efficacy-of-1166322/Esta buenísima noticia traerá un -15%
El ensayo de fase 3 confirma la alta eficacia de la vacuna contra la malaria R21/Matrix-Mhttps://www.reuters.com/business/healthcare-pharmaceuticals/second-malaria-vaccine-highly-protective-trial-results-show-2024-02-01/https://www.precisionvaccinations.com/2024/02/01/malaria-vaccine-adjuvant-found-very-effectivehttps://www.miragenews.com/phase-3-trial-confirms-high-efficacy-of-1166322/Esta buenísima noticia traerá un -15%
El ensayo de fase 3 confirma la alta eficacia de la vacuna contra la malaria R21/Matrix-Mhttps://www.reuters.com/business/healthcare-pharmaceuticals/second-malaria-vaccine-highly-protective-trial-results-show-2024-02-01/https://www.precisionvaccinations.com/2024/02/01/malaria-vaccine-adjuvant-found-very-effectivehttps://www.miragenews.com/phase-3-trial-confirms-high-efficacy-of-1166322/Esta buenísima noticia traerá un -15%
El ensayo de fase 3 confirma la alta eficacia de la vacuna contra la malaria R21/Matrix-Mhttps://www.reuters.com/business/healthcare-pharmaceuticals/second-malaria-vaccine-highly-protective-trial-results-show-2024-02-01/https://www.precisionvaccinations.com/2024/02/01/malaria-vaccine-adjuvant-found-very-effectivehttps://www.miragenews.com/phase-3-trial-confirms-high-efficacy-of-1166322/Esta buenísima noticia traerá un -15%
El ensayo de fase 3 confirma la alta eficacia de la vacuna contra la malaria R21/Matrix-Mhttps://www.reuters.com/business/healthcare-pharmaceuticals/second-malaria-vaccine-highly-protective-trial-results-show-2024-02-01/https://www.precisionvaccinations.com/2024/02/01/malaria-vaccine-adjuvant-found-very-effectivehttps://www.miragenews.com/phase-3-trial-confirms-high-efficacy-of-1166322/Esta buenísima noticia traerá un -15%
El ensayo de fase 3 confirma la alta eficacia de la vacuna contra la malaria R21/Matrix-Mhttps://www.reuters.com/business/healthcare-pharmaceuticals/second-malaria-vaccine-highly-protective-trial-results-show-2024-02-01/https://www.precisionvaccinations.com/2024/02/01/malaria-vaccine-adjuvant-found-very-effectivehttps://www.miragenews.com/phase-3-trial-confirms-high-efficacy-of-1166322/Esta buenísima noticia traerá un -15%